ArticleCureus2025
Exploring the Feasibility of the Creyos Cognitive Assessment Tool Among Patients With Heart Failure.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective The objective of this study is to explore the feasibility of the Creyos Cognitive Assessment Tool (Creyos, Toronto, Canada) as a cognitive testing instrument for patients with heart failure (HF). Background Identifying appropriate methods for cognitive testing among patients with HF is important to enable further study of their high prevalence of cognitive decline. Methods A total of 40 participants, composed of 30 outpatients with HF (75%) and 10 patients without HF (25%), were asked to complete all 12 online Creyos tests, which collectively measure short-term memory (STM), reasoning, concentration, and verbal ability. The participants had the option to complete the study at home or in person at the hospital if they did not have computer/tablet access. We explored completion rate and completion time and evaluated how our participants compared to a sex/age-matched healthy population (obtained from Creyos). Results Among 45 patients who consented to participate, five withdrew, and 40 (89%; median age: 68 {interquartile range (IQR): 59-76} years; 78% men) completed all 12 tests of cognition. Overall, the participants had a positive experience with the tool, with a median time for completion of 25.9 minutes. When compared to age- and sex-matched norms, 73% of participants with HF showed marked impairment (>1.5 standard deviations {SDs}), and 93% showed mild impairment (>1 standard deviation) on at least one test. Individuals with HF performed worse on the reasoning and verbal ability domains but better on the STM domain when compared to the age/sex-matched healthy population data provided by Creyos. Conclusion It is feasible to use Creyos as a cognitive assessment tool in the population with HF, and it may enable further exploration of the connections between cognitive function and heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.